St. Jude's renal denervation system nets EU thumbs up

Editorial Staff | | Health Imaging | Screening
St. Jude Medical has been granted CE Mark approval of its EnligHTN renal denervation system.

Renal denervation is an ablation procedure that seeks to reduce blood pressure in patients with hypertension that is resistant to medical therapy. Clinical data from the EnligHTN I trial about the safety and efficacy of this renal denervation technology will be presented on May 16 at EuroPCR in Paris.

Using the EnligHTN system, an ablation catheter delivers radiofrequency energy to create lesions along the renal sympathetic nerves. The system uses multi-electrode ablation technology. With the basket design, the placement of the ablation catheter allows a pattern of four ablations in 90-second intervals. 

St. Jude is based in St. Paul, Minn.

 

 

Editorial Staff

Related Content

What breast density status can tell us about cardiovascular risk
FDA clears AI tool that flags signs of heart disease in chest CT scans
Patients without PCPs struggle to access lung cancer screening, despite eligibility
Breast cancer rates among women in their 30s are on the rise
Singing radiologist pens song to clear up confusion about breast cancer screening recs
AI loaded onto mammography systems can flag possible cancers in real time to speed workflows

Around the web

Cardiovascular Business
Positron partners with Upbeat Cardiology Solutions to improve cardiac PET/CT access

Positron, a New York-based nuclear imaging company, will now provide Upbeat Cardiology Solutions with advanced PET/CT systems and services. 

Cardiovascular Business
Global shortage of nuclear imaging isotopes may be over

The nuclear imaging isotope shortage of molybdenum-99 may be over now that the sidelined reactor is restarting. ASNC's president says PET and new SPECT technologies helped cardiac imaging labs better weather the storm.

Cardiovascular Business
‘A huge win’: CMS significantly increases Medicare payments for cardiac CT

CMS has more than doubled the CCTA payment rate from $175 to $357.13. The move, expected to have a significant impact on the utilization of cardiac CT, received immediate praise from imaging specialists.